BLINDING Single blind Clause Samples
BLINDING Single blind. RANDOMIZATION A randomization code will be developed to enable placebo or active treatment within each cohort Agreement Re: Exercise of Stock Warrant SCHEDULE 4(f)-1 Form of Option Agreement OPTION AND LICENSE AGREEMENT THIS OPTION AND LICENSE AGREEMENT (the "Agreement") is entered into as of 15th day of April, 2003 (the "Effective Date"), by and between Chemokine Therapeutics Corp., a Delaware corporation, having a place of business at ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇., ▇▇▇▇▇ ▇▇▇, ▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ (hereinafter "Licensor"), and Pharmaceutical Product Development, Inc., a North Carolina corporation, having a place of business at ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ (hereinafter "Licensee").
BLINDING Single blind. RANDOMIZATION A randomization code will be developed to enable placebo or active treatment within each cohort Agreement Re: Exercise of Stock Warrant SCHEDULE 4(e)-2 Multi-Day Phase I Clinical Studies PROTOCOL TITLE A single blind, dose rising/MTD study of the safety, pharmacokinetics and pharmacodynamics of a once daily subcutaneous dosing x 5 days of CT-0214 administered to normal human volunteers. COMPOUND NUMBER CT-0214 COMPOUND NAME N/A DOSE/ROUTE/REGIMEN X - X mg/kg subcutaneous, single daily dose x 5 days SPONSOR Chemokine Therapeutics CLINICAL PHASE Phase I INDICATION Increased neutrophil and platelet production in male and female healthy normal volunteers.